Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today
All-cause mortality rates have declined substantially in several high-income countries, including England. A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex. Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially. Many studies have primarily focused on identifying multimorbidity patterns in the general population. The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
288
blood sample on EDTA
serum sample
Morning urine sample
New Valley University
Al Khārjah, Kharga Oasis, Egypt
RECRUITINGNumber of participants with hypertension
Time frame: At time of inclusion in the study
Number of participants with dyslipidemia
Time frame: At time of inclusion in the study
Number of participants with Diabetic kidney disease
Time frame: At time of inclusion in the study
Number of participants with Coronary heart disease
Time frame: At time of inclusion in the study
Number of participants with thyroid disorder
Time frame: At time of inclusion in the study
Number of participants with Stroke
Time frame: At time of inclusion in the study
Number of participants with Peripheral arterial disease
Time frame: At time of inclusion in the study
Number of participants with Diabetic eye disease
Time frame: At time of inclusion in the study
Number of participants with Peripheral neuropathy
Time frame: At time of inclusion in the study
Number of participants with Liver disease
Time frame: At time of inclusion in the study
Number of participants with Infections
Time frame: At time of inclusion in the study
Number of participants with Cancer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
serum sample
blood sample on EDTA
serum sample
serum sample
by electrocardiogram
imaging
serum sample
serum sample
Time frame: At time of inclusion in the study
Number of participants with controlled diabetes mellitus with correlation to the number of cormobidity
Time frame: At time of inclusion in the study
Correlate the presence of each co-morbidity with the extent of diabetes control
Time frame: At time of inclusion in the study